Drugs that contain Mitomycin

1. List of Jelmyto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9040074 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(7 years from now)

US9950069 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 15, 2027
New Product (NP) Apr 15, 2023

Market Authorisation Date: 15 April, 2020

Treatment: NA

Dosage: POWDER;PYELOCALYCEAL

More Information on Dosage

JELMYTO family patents

8

United States

4

Israel

2

European Union

1

Spain

1

Denmark

1

Germany

2. List of Mitosol drug patents

Can you believe MITOSOL received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9539241 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jan, 2028

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8186511 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jul, 2026

(3 years from now)

US9205075 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jul, 2026

(3 years from now)

US7806265 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Feb, 2029

(5 years from now)

US9649428 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
May, 2029

(5 years from now)

Market Authorisation Date: 07 February, 2012

Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery

Dosage: FOR SOLUTION;TOPICAL

More Information on Dosage

MITOSOL family patents

6

United States

2

Japan

2

European Union

1

Australia

1

Canada

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic